Evidence map›Paper›PMID 37648321›Full record

ArticleAnticancer research2023

Tristan M Sissung, Sarah Lochrin, Tyler Liu, Keith Schmidt, Jonathan Strope, Emily Risdon, Hyoyoung Choo-Wosoba, David J Venzon, Wiem Lassoued, Houssein A Sater and 3 more

Open access · hybridAbstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in Anticancer research, 2023. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 2 papers.

0numbers the graph read from it
0cells of the map it votes in
2citing papers in PubMed
0.6field-weighted citation impact, top 23% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

2 citing papers in PubMed, 2 citations in OpenAlex.

  1. Article
  2. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

13 authors at 2 institutions in 2 countries.

Tristan M SissungClinical Pharmacology Program, Center for Cancer Research, National Cancer Institute, Bethesda, MD, U.S.A.
Sarah LochrinClinical Pharmacology Program, Center for Cancer Research, National Cancer Institute, Bethesda, MD, U.S.A.
Tyler LiuClinical Pharmacology Program, Center for Cancer Research, National Cancer Institute, Bethesda, MD, U.S.A.
Keith SchmidtClinical Pharmacology Program, Center for Cancer Research, National Cancer Institute, Bethesda, MD, U.S.A.
Jonathan StropeMolecular Pharmacology Section, Center for Cancer Research, National Cancer Institute, Bethesda, MD, U.S.A.
Emily RisdonMolecular Pharmacology Section, Center for Cancer Research, National Cancer Institute, Bethesda, MD, U.S.A.
Hyoyoung Choo-WosobaBiostatistics and Data Management Section, Center for Cancer Research, National Cancer Institute, Bethesda, MD, U.S.A.
David J VenzonBiostatistics and Data Management Section, Center for Cancer Research, National Cancer Institute, Bethesda, MD, U.S.A.
Wiem LassouedGenitourinary Malignancies Branch, Center for Cancer Research, National Cancer Institute, Bethesda, MD, U.S.A.
Houssein A SaterGenitourinary Malignancies Branch, Center for Cancer Research, National Cancer Institute, Bethesda, MD, U.S.A.
Beatriz Walter-RodriguezGenitourinary Malignancies Branch, Center for Cancer Research, National Cancer Institute, Bethesda, MD, U.S.A.
Douglas K PriceMolecular Pharmacology Section, Center for Cancer Research, National Cancer Institute, Bethesda, MD, U.S.A.
William D FiggClinical Pharmacology Program, Center for Cancer Research, National Cancer Institute, Bethesda, MD, U.S.A. figgw@mail.nih.gov.
National Cancer Institute · USNational Cancer Institute · MY

Funding

Clinical PharmacogeneticsZIABC010627 · NCI · DIVISION OF BASIC SCIENCES - NCI · PI FIGG, WILLIAM DOUGLAS · 2009 to 2025
$13.9M
Clinical PharmacologyZ01BC010627 · NCI · DIVISION OF BASIC SCIENCES - NCI · PI FIGG, WILLIAM DOUGLAS · 2004 to 2008
$938k
Intramural NIH HHS Z01 BC010627Intramural NIH HHS ZIA BC010627
6 · The paper itself

Abstract

BACKGROUND/

aimGonadotropin-releasing hormone 2 (GNRH2) is a poorly-studied peptide hormone that is widely distributed in the central nervous system and expressed in peripheral tissues of mammals. The non-synonymous rs6051545 variant in GNRH2 (A16V) has been linked to higher serum testosterone concentrations. This study investigated whether the A16V variant is associated with altered androgen-deprivation therapy (ADT) progression-free survival (PFS) and overall survival (OS). PATIENTS AND

methodsWe examined the expression of GNRH2 in prostate tissue microarrays comprising normal tissue, prostatic hyperplasia, and prostate cancer using immunofluorescence. We also evaluated the GNRH2 genotype in 131 patients with prostate cancer who received ADT and compared PFS and OS between the variant and wild-type genotypes.

resultsGNRH2 was detected in all prostate tissues, although expression did not vary with Gleason grade or disease stage (p=0.71). The GNRH2 A16V genotype was not associated with PFS or OS; however, univariate and multivariate analyses revealed Gleason score and definitive local therapy were each associated with PFS (p≤0.0074), whereas age and Gleason score were associated with OS (p≤0.0046).

conclusionGNRH2 is expressed in normal, hyperplastic, and neoplastic prostate tissues; the A16V variant is not related to treatment outcome or survival.

Indexed as

Prostatic HyperplasiaProstatic NeoplasmsAndrogen AntagonistsAndrogensAnimalsGonadotropin-Releasing HormoneHumansMaleMammalsAndrogen AntagonistsAndrogensGonadotropin-Releasing Hormoneandrogen deprivation therapyGNRH2prostate cancersurvival

Identifiers

PMID37648321
PMCPMC10760530
OpenAlexW4386283551

What OpenQuestion holds

Textmetadata
LicenceTDM
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.